May 29, 2014Novozymes Biopharma enters agreement with a leading vaccine company to conduct research on a novel subunit vaccine complex based on albumin fusion technologyMay 12, 2014Novozymes Biopharma to offer drug-albumin conjugation platform in collaboration with ThioLogicsApril 24, 2014Novozymes' half-life extension technology reaches landmark milestone as GlaxoSmithKline's albiglutide is granted FDA marketing approvalMarch 31, 2014Novozymes VELTIS® half-life extension technology used by GlaxoSmithKline in type 2 diabetes drug approved in Europe
March 13, 2014Novozymes Biopharma announces collaboration with Janssen to evaluate proprietary VELTIS half-life extension technology
January 21, 2014Novozymes Biopharma announces new data highlighting potential for monthly drug dosing
René TronborgCorporate Press ManagerTel.: +45 44462274Fax: +45 email@example.com
Thomas Steenbech BomhoffSenior Manager of Investor RelationsTel.: +1 919 494 3483Fax: +1 919 494 3473Click here to email
Novozymes Biopharma is a part of Novozymes A/S and is listed on the NASDAQ, trading as NZYM B.
Copyright © 2015 Novozymes. All rights reserved.